Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 1
2006 2
2008 3
2009 1
2010 3
2011 2
2012 11
2013 6
2014 4
2015 14
2016 10
2017 6
2018 12
2019 20
2020 26
2021 31
2022 24
2023 23
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K; XTEND-1 Trial Group. von Drygalski A, et al. Among authors: jimenez yuste v. N Engl J Med. 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226. N Engl J Med. 2023. PMID: 36720133 Clinical Trial.
Principles of care for acquired hemophilia.
Dolan G, Benson G, Bowyer A, Eichler H, Hermans C, Jiménez-Yuste V, Ljung R, Pollard D, Santagostino E, Šalek SZ. Dolan G, et al. Among authors: jimenez yuste v. Eur J Haematol. 2021 Jun;106(6):762-773. doi: 10.1111/ejh.13592. Epub 2021 Mar 18. Eur J Haematol. 2021. PMID: 33527471 Free PMC article. Review.
International recommendations on the diagnosis and treatment of acquired hemophilia A.
Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, Di Minno G, d'Oiron R, Salaj P, Jiménez-Yuste V, Huth-Kühne A, Giangrande P. Tiede A, et al. Among authors: jimenez yuste v. Haematologica. 2020 Jul;105(7):1791-1801. doi: 10.3324/haematol.2019.230771. Epub 2020 May 7. Haematologica. 2020. PMID: 32381574 Free PMC article.
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Matsushita T, et al. Among authors: jimenez yuste v. N Engl J Med. 2023 Aug 31;389(9):783-794. doi: 10.1056/NEJMoa2216455. N Engl J Med. 2023. PMID: 37646676 Clinical Trial.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. Callaghan MU, et al. Among authors: jimenez yuste v. Blood. 2021 Apr 22;137(16):2231-2242. doi: 10.1182/blood.2020009217. Blood. 2021. PMID: 33512413 Free PMC article. Clinical Trial.
International consensus recommendations on the management of people with haemophilia B.
Hart DP, Matino D, Astermark J, Dolan G, d'Oiron R, Hermans C, Jiménez-Yuste V, Linares A, Matsushita T, McRae S, Ozelo MC, Platton S, Stafford D, Sidonio RF Jr, Tiede A. Hart DP, et al. Among authors: jimenez yuste v. Ther Adv Hematol. 2022 Apr 2;13:20406207221085202. doi: 10.1177/20406207221085202. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35392437 Free PMC article. Review.
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jiménez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Négrier C, et al. Among authors: jimenez yuste v. Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27. Lancet Haematol. 2023. PMID: 36716761 Clinical Trial.
Hemophilia treatment in 2021: Choosing the"optimal" treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians.
Hermans C, Noone D, Benson G, Dolan G, Eichler H, Jiménez-Yuste V, Königs C, Lobet S, Pollard D, Zupančić-Šalek S, Mancuso ME. Hermans C, et al. Among authors: jimenez yuste v. Blood Rev. 2022 Mar;52:100890. doi: 10.1016/j.blre.2021.100890. Epub 2021 Sep 29. Blood Rev. 2022. PMID: 34736780 Free article. Review.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Mahlangu J, et al. Among authors: jimenez yuste v. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550. N Engl J Med. 2018. PMID: 30157389 Free article. Clinical Trial.
187 results